Table 5.
The prevalence of different HPV types combination in 6286 women, China, stratified by pathology n (%).
| Genotyping | Total # (n = 6091) |
Negative (n = 5861) |
CIN1 (n = 98) |
CIN2 (n = 68) |
CIN3 (n = 59) |
Cancer (n = 5) |
CIN2+ (n = 132) |
|---|---|---|---|---|---|---|---|
| HPV6/11 | 66 (1.1) | 61 (1.0) | 3 (3.1) | 1 (1.5) | 0 (0.0) | 1 (20.0) | 2 (1.5) |
| 14 HR-HPV | 1117 (18.3) | 923 (15.7) | 75 (76.5) | 58 (85.3) | 56 (94.9) | 5 (100.0) | 119 (90.2) |
| Other LR-HPV26/40/43/44/53/54/69/70/71/73/74/82 | 399 (6.6) | 362 (6.2) | 20 (20.4) | 12 (17.6) | 4 (6.8) | 1 (20.0) | 17 (12.9) |
| Vaccines approved by NMPA | |||||||
| HPV16/18 | 331 (5.4) | 220 (3.8) | 28 (28.6) | 37 (54.4) | 41 (69.5) | 5 (100.0) | 83 (62.3) |
| HPV6/11/16/18 | 392 (6.4) | 279 (4.8) | 30 (30.6) | 37 (54.4) | 41 (69.5) | 5 (100.0) | 83 (62.3) |
| HPV6/11/16/18/31/33/45/52/58 | 818 (13.4) | 639 (10.9) | 65 (66.3) | 55 (80.9) | 54 (91.5) | 5 (100.0) | 114 (86.4) |
| Vaccines in clinical trial # | |||||||
| HPV16/18/58 | 438 (7.2) | 294 (5.0) | 46 (46.9) | 47 (69.1) | 46 (78.0) | 5 (100.0) | 98 (74.2) |
| HPV16/18/52/58 | 644 (10.6) | 480 (8.2) | 56 (57.1) | 52 (76.5) | 51 (86.4) | 5 (100.0) | 108 (81.8) |
| HPV6/11/16/18/31/33/45/52/58/59/68 | 901 (14.8) | 722 (12.3) | 65 (66.3) | 55 (80.9) | 54 (91.5) | 5 (100.0) | 114 (86.4) |
| HPV6/11/16/18/31/33/35/39/45/51/52/56/58/59 | 1059 (17.4) | 868 (14.8) | 73 (74.5) | 57 (83.8) | 56 (94.9) | 5 (100.0) | 118 (89.4) |
# A total number of 6,286,285 cases without pathological data were excluded; cervical intraepithelial neoplasia grade 2 (CIN2); cervical intraepithelial neoplasia grade 3 (CIN3).